RecoveryPreliminary grade

SS-31

Elamipretide

Mitochondria-targeting tetrapeptide — FDA-approved for Barth syndrome (2025), strong safety record, near-zero gray-market supply.

Verdict — C · Emerging / Mixed

A genuine FDA approval backed by phase-3 data in a rare disease, with a clean safety record. But the approved indication is narrow, and essentially no verified gray-market supply exists for the off-label longevity/performance use case. A C today pending broader clinical development.

PepScore / 100

CEmerging / Mixed

How we compute this →

Overview

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that stabilizes cardiolipin in the inner mitochondrial membrane, improving ATP synthesis and reducing oxidative stress. It received FDA approval in 2025 for Barth syndrome (a rare pediatric cardiomyopathy) following positive TAZPOWER phase-3 data. Beyond this narrow indication, it has been studied for heart failure, aging, and ischemia-reperfusion injury. Gray-market supply is extremely limited and largely unverifiable; the compound is not commercially manufactured for consumer use.

PepScore Breakdown — the four axes

Evidence

35% weight

75/100

How strong is the published human science?

Human data depth28/40

Regulatory & registry status24/30

Reproducibility & consistency14/20

Mechanism characterized in humans9/10

Sourcing & COA

30% weightOur moat

40/100

Can a buyer obtain an independently-verified, high-purity version? — our proprietary layer.

Independent 3rd-party testing14/35

Verified purity %12/30

COA transparency & batch traceability8/20

Multi-vendor verified availability6/15

Safety & Risk

25% weight

77/100

What is the real-world harm potential?

Documented AEs / toxicity32/40

Contraindication breadth19/25

Regulatory warnings14/20

Therapeutic index / margin12/15

Practicality

10% weight

50/100

How easy is it to actually run a verified version?

Verified-source availability14/35

Cost / value per cycle12/25

Reconstitution & administration16/25

Storage & stability8/15

Sources & Citations

Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.

Want a clinical path?

Talk to a licensed provider about SS-31 and whether it's appropriate for your situation.

Talk to a Provider ↗

Telehealth. Not medical advice — for educational purposes.

PepScore63/100 · C

Last gradedJune 28, 2026

Next re-grade triggerPhase-2b/3 results in heart failure or aging would lift Evidence; a licensed compounding pathway would lift Sourcing and Practicality.

Price Index Vendor Grades Providers COA Lookup All Rankings

Get the PepEvolution Dispatch

Monthly COA findings, vendor changes, and new grades. Research/educational only — no spam.

Free. Unsubscribe anytime. Research/educational content only.

Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.